Skip to main content

Pasithea Therapeutics Corp.

KTTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001841330

In the last 90 days, Pasithea Therapeutics Corp. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q2 2026, worth $8.66M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 17, 2026
$16.0M
Insider buysLast 90 days, $805.9K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +5 vs. previous quarter
25
13F valueReported value at the end of Q2 2026
$8.66M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$20.4M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
386.7K
Shares sold short
Change
+212.1K
+121.5% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding KTTA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding KTTA at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Pasithea Therapeutics Corp. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)8:42 PM ETNov 13-174 daysCoastlands Capital LP10% OwnerPPurchase+1.67M$0.4833+$805.9K+43.5%5.50M after3 lots
Jun 22, 2026 (view filing)Jun 175 daysCoastlands Capital LP10% OwnerPPurchase+100.0K$0.53+$53.0K+2.7%3.84M after
Dec 1, 2025 (view filing)Nov 283 daysSteinman LawrenceDirectorPPurchase+133.3K$0.75+$100.0K+200.9%199.7K after
Dec 1, 2025 (view filing)Nov 283 daysMarques TiagoChief Executive OfficerPPurchase+33.3K$0.75+$25.0K+83.3%73.3K after
Dec 1, 2025 (view filing)Nov 283 daysDumesnil SimonDirectorPPurchase+33.3K$0.75+$25.0K+1,333.3%35.8K after
May 14, 2025 (view filing)May 122 daysMarques TiagoChief Executive OfficerSSale−960$0.83−$796.8−2.3%40.0K after
Jun 6, 2023 (view filing)9:00 PM ETJun 24 daysSteinman LawrenceDirectorPPurchase+30.0K$0.431+$12.9K+2.3%1.33M after
Oct 19, 2022 (view filing)5:29 PM ETOct 172 daysDelaney David and 2 othersOther: Member of 10% owner groupPPurchase+1.00K$1.11+$1.11K+0.4%227.5K after
Sep 30, 2022 (view filing)4:36 PM ETSep 28-292 daysCamac Fund, LP and 3 othersOther: Member of 10% owner groupPPurchase+64.4K$1.19+$76.3K+3.7%1.79M after2 lots
Sep 6, 2022 (view filing)5:03 PM ETSep 1-65 daysCamac Fund, LP and 3 othersOther: Member of 10% owner groupPPurchase+88.9K$1.13+$100.4K+5.4%1.72M after3 lots

Top 10 13F holders, Q2 2026

See all 25 holders

The largest institutional positions in Pasithea Therapeutics Corp. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding KTTA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Cable Car Capital LLC3,000,000$1.55M0.03%+1,793,621+148.7%Added
Stonepine Capital Management, LLC2,201,468$1.13M0.86%+1,370,167+164.8%Added
Jupiter Topco LLC2,100,000$1.09M0.00%+2,100,000New
Adage Capital Partners GP, L.L.C.2,100,000$1.08M0.00%00.0%Unchanged
Opaleye Management Inc.2,050,000$1.06M0.10%+2,050,000New
Ameriprise Financial Inc1,864,485$961.0K0.00%+513,589+38.0%Added
Squadron Capital Management LLC1,000,000$515.4K0.18%−1,100,000−52.4%Reduced
AdvisorShares Investments LLC937,550$483.2K0.06%+600,042+177.8%Added
Vivo Capital, LLC465,471$239.9K0.02%−1,634,529−77.8%Reduced
Persistent Asset Partners Ltd290,555$149.8K0.05%00.0%Unchanged

Holders of 5% or more of KTTA

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Pasithea Therapeutics Corp..

Largest holders of KTTA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Coastlands Capital LP13G/A11.48%3.84M shares+1.49 ppfrom 9.99%Feb 27, 20262 filingsJul 1, 2026SEC
Janus Henderson Group PLC13G9.99%10.2M sharesNewDec 8, 20251 filingDec 8, 2025SEC
Vivo Opportunity Fund Holdings, L.P.13G/A9.99%9.20M shares0.00 ppfrom 9.99%Dec 5, 20253 filingsNov 16, 2026SEC
Adage Capital Management, L.P.13G9.99%2.33M sharesNewFeb 12, 20261 filingFeb 12, 2026SEC
Squadron Capital Management LLC13G/A9.90%2.33M shares0.00 ppfrom 9.90%Dec 5, 20252 filingsFeb 17, 2026SEC